{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:21:18Z","timestamp":1790724078852,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":4052,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1111\/j.1538-7836.2011.04498.x","type":"journal-article","created":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T13:01:19Z","timestamp":1317819679000},"page":"2168-2175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":266,"title":["Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non\u2010valvular atrial fibrillation from the RE\u2010LY trial"],"prefix":"10.1016","volume":"9","author":[{"given":"K.\u2010H.","family":"LIESENFELD","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"LEHR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"DANSIRIKUL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"REILLY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"CONNOLLY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"EZEKOWITZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"YUSUF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"WALLENTIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"HAERTTER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"STAAB","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0010","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0015","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2165\/00003088-199630060-00002","article-title":"Clinically important drug interactions with anticoagulants. An update","volume":"30","author":"Harder","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0025","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0035","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open\u2010label, parallel\u2010group, single\u2010centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0045","doi-asserted-by":"crossref","unstructured":"Stangier J, Staehle H, Rathgen K, Roth W, Reseski K, Koernicke T. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol; DOI: 10.1177\/0091270010393342.","DOI":"10.1177\/0091270010393342"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0050","unstructured":"Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. 2001."},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0055","first-page":"3431","article-title":"Full model estimation approach for covariate effects: inference based on clinical importance and estimation precision","volume":"6","author":"Gastonguay","year":"2004","journal-title":"AAPS J"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0060","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model","volume":"37","author":"Ette","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl\u2010speaks\u2010NONMEM (PsN) \u2013 a perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0070","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","article-title":"Population pharmacokinetics and pharmacodynamics of once\u2010 and twice\u2010daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0075","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1538-7836.2009.03298.x","article-title":"The pharmacokinetics of idraparinux, a long\u2010acting indirect factor\u00a0Xa inhibitor: population pharmacokinetic analysis from Phase\u00a0III clinical trials","volume":"7","author":"Veyrat\u2010Follet","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF01062336","article-title":"Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics","volume":"10","author":"Boxenbaum","year":"1982","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1111\/j.1538-7836.2011.04498.x_bb0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2011.04498.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622074475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622074475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2011.04498.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:52:57Z","timestamp":1761533577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622074475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1538783622074475"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04498.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non\u2010valvular atrial fibrillation from the RE\u2010LY trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04498.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}